Citalopram: a comprehensive review

Bibliography

• HOLDEN C: Global Survey examines impact of depres-sion. Science (2000) 288:39–40.
   PubMedGoogle Scholar
• DUPONT RL: Panic disorder and addiction: the clinicalissues of co-morbidity. Bull. Menninger Clin. (1997) 61:A54–65.
   PubMed Web of Science ®Google Scholar
• STEELE C, ROVNER B, CHASE GA et al: Psychiatricsymptoms and nursing home placement of patients with Alzheimer's disease. Am. J. Psychiatry (1990) 147:1049–1051.
   PubMed Web of Science ®Google Scholar
• HYTTEL J: Pharmacological characterization of selective serotonin reuptake inhibitors (SSRIs). Int. Psychopharmacol. (1994) 9:19–26.
   PubMedGoogle Scholar
• HYTTEL J, ARNT J, SANCHEZ C: The pharmacology of citalopram. Rev. Contemp. Pharmacother. (1995) 6:271–285.
   Google Scholar
• NOBLE S, BENFIELD P: Citalopram: A review of its pharmacology, clinical efficacy and tolerability in the treatment of depression. CNS Drugs (1997) 8:410–431.
   Web of Science ®Google Scholar
• HYTTEL J, BOGES KP, PERREGAARD J et al.: The pharma-cological effect of citalopram resides in the (S)-(+)-enantiomer. J. Neural. Transm. Gen. Sect. (1992) 88:157–160.
   PubMed Web of Science ®Google Scholar
• JOUBERT AF, STEIN DJ: Citalopram and anxiety disorders. Reviews in Contemporary Pharmacotherapy (1999) 10:79–123.
   Google Scholar
• BAUMANN P, LARSEN F: The pharmacokinetics of citalopram. Rev. Contemp. Pharmocother. (1995) 6:287–295.
   Google Scholar
• FOGLIA JP, POLLOCK BG, KIRSHNER MA et al.: Plasmalevels of citalopram enantiomers and metabolites in elderly patients. Psychopharmacol. Bull. (1997) 33:109–112.
   PubMed Web of Science ®Google Scholar
• JOFFE P, LARSEN FS, PEDERSEN V et al.: Single-dose pharmacokinetics of citalopram in patients with moderate renal insufficiency or hepatic cirrhosis compared with healthy subjects. Eur.J. Clin. Pharmacol. (1998) 54:237–242.
   PubMed Web of Science ®Google Scholar
• GUTIERREZ M, ABRAMOWITZ W: Steady-state pharma-cokinetics of citalopram in young and elderly subjects. Pharmacotherapy (2000) 20:1441–1447.
   PubMed Web of Science ®Google Scholar
• GREENBLATT DJ, VON MOLTKE LL, HARMATZ JS et al.: Human cytochromes and some newer antidepres-sants: Kinetics, metabolism and drug interactions. J Clin. Psychopharmacol. (1999) 19:23S–35S.
   Google Scholar
• VON MOLTKE LL, GREENBLATT DJ, GRASSI JM et al.:Citalopram and desmethylcitalopram in vitro: human cytochromes mediating transformation and cytochrome inhibitory effects. Biol. Psychiatry (1999) 46:839–849.
   PubMed Web of Science ®Google Scholar
• ROCHAT B, AMEY M, GILLET M et al.: Identification of three cytochrome P450 isozymes involved in N-demethylation of citalopram enantiomers in human liver microsomes. Transient expression of the serotonin transporter in the developing mouse thalamocortical system. Pharmacogenetics (1997) 7:1–10.
   Google Scholar
• VAN HARTEN J: Clinical pharmacokinetics of selective serotonin re-uptake inhibitors. Clin. Pharmacokinet. (1993) 24:203–220.
   PubMed Web of Science ®Google Scholar
• MENDELS J, KIEV A, FABRE LF: Double-blind comparison of citalopram and placebo in depressed out-patients with melancholia. Depress. Anxiety (1999) 9:54–60.
   PubMedGoogle Scholar
• FEIGHNER JP, OVERO K: Multicenter, placebo-controlled, fixed dose study of citalopram in moderate to severe depression. J. Clin. Psychiatry (1999) 60:824–830.
   PubMed Web of Science ®Google Scholar
• NYTH AL, GOTTFRIES CG, LYBY K et al.: A controlledmulticenter clinical study of citalopram and placebo in elderly depressed patients with and without concomitant dementia. Acta. Psychiatr. Scand. (1992) 86:138–145.
   PubMed Web of Science ®Google Scholar
• MONTGOMERY SA, PEDERSEN V, TANGHOJ P et al.: The optimal dosing regimen for citalopram-a meta-analysis of nine placebo-controlled studies. Int. Psychopharmacol (1994) 9 (Suppl. 1):35–40.
   Google Scholar
• FLICKER C, TANGHOJ P, TSAY J-Y: Meta-analysis of placebo-controlled trials of citalopram in the treatment of depression. American Psychiatric Associa-tion Meeting. Toronto, Ontario, Canada (1998).
   Google Scholar
• STAHL SM: Placebo-controlled comparison of the selective serotonin re-uptake inhibitors citalopram and sertraline. Biol. Psychiatry (2000) 48:894–901.
   PubMed Web of Science ®Google Scholar
• GRAVEM A, AMTHOR KF, ASTRUP C et al.: A double-blind comparison of citalopram (Lu 10-171) and amitrip-tyline in depressed patients. Acta Psychiatr. Scand. (1987) 75:478–486.
   PubMedGoogle Scholar
• SHAW DM, THOMAS DR, BRISCOE MH et al.: A comparison of the antidepressant action of citalo-pram and amitriptyline. Br. J. Psychiatry (1986) 149:515–517.
   PubMed Web of Science ®Google Scholar
• KYLE CJ, PETERSEN HE, OVERO KF: Comparison of the tolerability and efficacy of citalopram and amitrip-tyline in elderly depressed patients treated in general practice. Depress. Anxiety (1998) 8:147–153.
   PubMedGoogle Scholar
• ROSENBERG C, DAMSBO N, FUGLUM E et al.: Citalopram and imipramine in the treatment of depressive patients in general practice. A Nordic multicentre clinical study. Int. Clin. Psychopharmacol. (1994) 9 (Suppl. 0:41–48.
   Google Scholar
• BOUCHARD JM, DELAUNAY J, DELISLE JP et al.: Citalo-pram versus maprotiline: a controlled, clinical multicentre trial in depressed patients. Acta Psychiatr. Scand. (1987) 76:583–592.
   PubMed Web of Science ®Google Scholar
• TIMMERMAN L, DE BEURS P, TAN BK et al: A double- blind comparative clinical trial of citalopram vs. maprotiline in hospitalized depressed patients. Int. Psychopharmacol. (1987) 2:239–253.
   PubMedGoogle Scholar
• AHLFORS UG, ELOVAARA S, HARMA P et al: Clinical multi-centre study of citalopram compared double-blindly with mianserin in depressed patients in Finland. Nord. Psykiatr. Tidsskr. (1988) 42:201–210.
   Google Scholar
• DE WILDE J, MERTENS C, OVERO KF et al: Citalopram versus mianserin. A controlled, double-blind trial in depressed patients. Acta. Psychiatr. Scand. (1985) 72:89–96.
   PubMedGoogle Scholar
• KARLSSON I, GODDERIS J, AUGUSTO DE MENDONCA LIMA C et al.: A randomised, double-blind comparison of the efficacy and safety of citalopram compared to mianserin in elderly, depressed patients with or without mild to moderate dementia. Int. j Geriatr. Psychiatry (2000) 15:295–305.
   Google Scholar
• DANISH UNIVERSITY ANTIDEPRESSANT GROUP: Citalo-pram: clinical effect profile in comparison with clomipramine. A controlled multicenter study. Psycho-pharmacology (1986) 90:131–138.
   Google Scholar
• BECH P, CIALDELLA P: Citalopram in depression-meta-analysis of intended and unintended effects. Int. Clin. Psychopharmacol. (1992) 6 (Suppl. 5):45–54.
   Google Scholar
• HAFFMANS PM, TIMMERMAN L, HOOGDUIN CA: Efficacy and tolerability of citalopram in comparison with fluvoxamine in depressed out-patients: a double-blind, multicentre study. The LUCIFER Group . Int. Clin. Psychopharmacol. (1996) 11:157–164.
   PubMed Web of Science ®Google Scholar
• BOUGEROL T, SCOTTO JC, PATRIS M et al.: Citalopram and fluoxetine in major depression - Comparison of two clinical trials in a psychiatrist setting and in general practice. Clinical Drug Investigation (1997) 14:77–89.
   Web of Science ®Google Scholar
• PATRIS M, BOUCHARD JM, BOUGEROL T et al.: Citalo-pram versus fluoxetine: a double-blind, controlled, multicentre, Phase III trial in patients with unipolar major depression treated in general practice. Int. Clin. Psychopharmacol. (1996) 11:129–136.
   PubMedGoogle Scholar
• EKSELIUS L, VON KNORRING L, EBERHARD G: A double-blind multicenter trial comparing sertraline and citalopram in patients with major depression treated in general practice. Int. Clin. Psychopharmacol. (1997) 12:323–331.
   PubMed Web of Science ®Google Scholar
• LEINONEN E, SKARSTEIN J, BEHNKE K et al:Efficacy andtolerability of mirtazapine versus citalopram: A double-blind, randomized study in patients with major depressive disorder. Int. Clin. Psychopharmacol. (1999) 14:329–337.
   PubMed Web of Science ®Google Scholar
• MONTGOMERY SA: Efficacy in long-term treatment ofdepression. J Clin. Psychiatry (1996) 2:24–30.
   Google Scholar
• MONTGOMERY SA, RASMUSSEN JG, TANGHOJ P: A 24-week study of 20 mg citalopram, 40 mg citalopram and placebo in the prevention of relapse of major depression. Int. Clin. Psychopharmacol (1993) 8:181–188.
   PubMed Web of Science ®Google Scholar
• ROBERT P, MONTGOMERY SA: Citalopram in doses of20-60 mg is effective in depression relapse prevention: a placebo-controlled 6 month study. Int. Clin. Psycho-pharmacol (1995) 10:29–35.
   PubMed Web of Science ®Google Scholar
• HOCHSTRASSER B, ISAKSEN PM, KOPONEN H et al.: Prophylactic effect of citalopram in unipolar, recurrent depression: a placebo-controlled study on maintainence therapy. Br. J. Psychiatry (2001) 178:304–310.
   PubMed Web of Science ®Google Scholar
• KLYSNER R, PLEDRUB E, HANSEN HL et al.:The effective-ness of citalopram in the prevention of depression recurrence in elderly patients. Annual meeting of the American Psychiatric Association. Chicago, USA (2000).
   Google Scholar
• DSM-W: Diagnostic and Statistical Manual of Mental Disorders. (Edition 4 American Psychiatric Press, Washington, DC (1994).
   Google Scholar
• FRANCHINI L, ZANARDI R, GASPERINI M et al.: Two-year maintenance with citalopram, 20 mg, in unipolar subjects with high recurrence rate. J Clin. Psychiatry (1999) 60:861–865.
   PubMed Web of Science ®Google Scholar
• NIERENBERG AA, WRIGHT EC: Evolution of remission as the new standard in the treatment of depression. J Clin. Psychiatry (1999) 60:7–11.
   PubMed Web of Science ®Google Scholar
• TZANAKAKI M, GUAZZELLI M, NIMATOUDIS I et al.: Increased remission rates with venlafaxine compared with fluoxetine in hospitalized patients with major depression and melancholia [published erratum appears in. Int. Clin. Psychopharmacol. (2000) Mar;15(2):120]. Int. Clin. Psychopharmacol. (2000) 15:29–34.
   Google Scholar
• ANDERSEN G, VESTERGAARD K, LAURITZEN L: Effective treatment of poststroke depression with the selective serotonin re-uptake inhibitor citalopram [see comments]. Stroke (1994) 25:1099–1104.
   PubMed Web of Science ®Google Scholar
• BOWDEN C: Citalopram versus imipramine in the treatment of in-patient depression: Results from a double-blind, placebo-controlled trial. American Psychiatric Association Meeting. Toronto, Ontario, Canada (1998).
   Google Scholar
• STAHL S, NIERENBERG A, GORMAN J: Evidence of early onset of antidepressant effect in randomized controlled trials. J Clin. Psychiatry (2001) 62 (Suppl. 017–23.
   Google Scholar
• JEFFERSON JW, GREIST JH: A double-blind comparison of citalopram and paroxetine in the treatment of patients with depression and anxiety. Annual Meeting of the American College of Neuropsychopharmaocology. San Juan, Puerto Rico (2000).
   Google Scholar
• HUMBLE M, WISTEDT B: Serotonin, panic disorder and agoraphobia: short-term and long-term efficacy of citalopram in panic disorders. Int. Clin. Psychophar-macol. (1992) 5:21–39.
   Google Scholar
• LEPOLA U, KOPONEN H, LEINONEN E: Citalopram in the treatment of social phobia: a report of three cases. Pharmacopsychiatry (1994) 27:186–188.
   PubMedGoogle Scholar
• LEPOLA U, LEINONEN E, KOPONEN H: Citalopram in the treatment of early-onset panic disorder and school phobia. Pharmacopsychiatry (1996) 29:30–32.
   PubMedGoogle Scholar
• WADE AG, LEPOLA U, KOPONEN HJ et al: The effect of citalopram in panic disorder. Br. J Psychiatry (1997) 170:549–553.
   PubMed Web of Science ®Google Scholar
• LEPOLA UM, WADE AG, LEINONEN EV et al.: A controlled, prospective, 1-year trial of citalopram in the treatment of panic disorder. J an. Psychiatry. (1998) 59:528–534.
   Google Scholar
• LEINONEN E, LEPOLA U, KOPONEN H et al: Citalopram controls phobic symptoms in patients with panic disorder: Randomized controlled trials. J Psychiatry NeuroscL (2000) 25:24–32.
   PubMed Web of Science ®Google Scholar
• KOPONEN H, LEPOLA U, LEINONEN E et al.: Citalopram in the treatment of obsessive-compulsive disorder: An open pilot study. Acta Psychiatr. Scand.(1997) 96:343–346.
   PubMed Web of Science ®Google Scholar
• THOMSEN PH: Child and adolescent obsessive-compulsive disorder treated with citalopram: Findings from an open trial of 23 cases. J. Child Adolesc. Psychopharmacol. (1997) 7:157–166.
   PubMed Web of Science ®Google Scholar
• MONTGOMERY S, KASPER S, STEIN DJ et al.: Citalopram 20 mg, 40 mg and 60 mg are all effective and well-tolerated compared with placebo in obsessive-compulsive disorder. Int. Clin. Psychopharmacol (2001) 16:75–86.
   PubMed Web of Science ®Google Scholar
• BOUWER C, STEIN DJ: Use of the selective serotoninre-uptake inhibitor citalopram in the treatment of generalized social phobia. J Affect. Disord. (1998) 49 :79–82.
   PubMed Web of Science ®Google Scholar
• BULLOCK K, HARTSON H, ELLIOTT M et al.: Citalopram treatment of compulsive shopping: an open-label pilot study. Annual Meeting of the College of Neuropsychophar-macology. San Juan, Puerto Rico (2000).
   Google Scholar
• STEIN DJ, BOUWER C, MAND CM: Use of the selective serotonin re-uptake inhibitor citalopram in treatment of trichotillomania. Eur. Arch. Psychiatry Clin. NeuroscL (1997) 247:234–236.
   PubMed Web of Science ®Google Scholar
• BALLDIN J, BERGGREN U, ENGEL J et al.: Effect of citalo-pram on alcohol intake in heavy drinkers. Alcohol. Clin. Exp. Res. (1994) 18:1133–1136.
   PubMedGoogle Scholar
• ANGELONE SM, BELLINI L, DI BELLA D et al.: Effects of fluvox amine and citalopram in maintaining abstinence in a sample of Italian detoxified alcoholics. Alcohol (1998) 33:151–156.
   Google Scholar
• NARANJO CA, KNOKE DM, BREMNER KE: Variations in response to citalopram in men and women with alcohol dependence. J. Psychiatry. NeuroscL (2000) 25:269–275.
   PubMed Web of Science ®Google Scholar
• ERIKSSON E: Serotonin re-uptake inhibitors for the treatment of premenstrual dysphoria. Int. Clin. Psycho-pharmacol. (1999) 1 4 (Suppl. 2):527–533.
   Google Scholar
• WIKANDER I, SUNDBLAD C, ANDERSCH B et al.: Citalo-pram in premenstrual dysphoria: is intermittent treatment during luteal phases more effective than continuous medication throughout the menstrual cycle? J. Clin. Psychopharmacol. (1998) 18:390–398.
   PubMed Web of Science ®Google Scholar
• TERI L: Behavior and caregiver burden: behavioralproblems in patients with Alzheimer's disease and its association with caregiver distress. Alzheimer Dis. Assoc. Disord. (1997) 11 (Suppl. 4):S35–S38.
   Google Scholar
• POLLOCK BG, MULSANT BH: Behavioral disturbances of dementia. J. Geriatr. Psychiatry Neurol. (1998) 11:206–212.
   PubMed Web of Science ®Google Scholar
• KATZ IR, JESTE DV, MINTZER JE et al.: Comparison of risperidone and placebo for psychosis and behavioral disturbances associated with dementia: a randomized, double-blind trial. Risperidone Study Group. J. Clin. Psychiatry. (1999) 60:107–115.
   PubMed Web of Science ®Google Scholar
• NYTH AL, GOTTFRIES CG: The clinical efficacy of citalo-pram in treatment of emotional disturbances in dementia disorders. A Nordic multicentre study. Br. J Psychiatry (1990) 157 :894–901.
   PubMed Web of Science ®Google Scholar
• POLLOCK BG, ROSEN J, MULSANT B et al.: Placebo-controlled comparison of citalopram versus perphe-nazine for acute treatment of severe beahioural distur-bances associated with demntia. American Association of Geriatric Psychiatry Meeting. San Fransico, CA, USA (2001).
   Google Scholar
• ANDERSEN G, VESTERGAARD K, RIIS JO: Citalopram for post-stroke pathological crying [see comments]. Lancet (1993) 342:837–839.
   PubMed Web of Science ®Google Scholar
• FEIGHNER J, OVERO K, FIEVE R et al.: Fixed dose comparison of citalopram versus placebo in the treatment of out-patients with moderate to severe depression. American Psychiatric Association Meeting. San Diego, CA (1998).
   Google Scholar
• MULDOON C: The safety and tolerability of citalopram. Int. Clin. Psychopharmacol (1996) 11:35–40.
   PubMedGoogle Scholar
• MONTGOMERY SA, RASMUSSEN JG, LYBY K et al.: Dose response relationship of citalopram 20 mg, citalo-pram 40 mg and placebo in the treatment of moderate and severe depression. Int. Clin. Psychopharmacol. (1992) 6:65–70.
   PubMed Web of Science ®Google Scholar
• HAKKARAINEN H, TANGHOJ P: Adverse event profile of citalopram in the elderly. American Association of Geriatric Psychiatry Meeting. San Diego, CA, USA (1998).
   Google Scholar
• SEGRAVES RT: Antidepressant-induced sexual dysfunc-tion. J. Clin. Psychiatry (1998) 59:48–54.
   PubMed Web of Science ®Google Scholar
• WALDINGER M, ZWINDERMAN A, OLIVIER B: SSRIs and ejaculation: A double-blind, randomized, comparative fixed-dose study with paroxetine and citalopram. American Psychiatric Association Annual Meeting. Chicago, IL, USA (2000).
   Google Scholar
• WALDINGER MD, HENGEVELD MW, ZWINDERMAN AH et al.: Effect of SSRI antidepressants on ejaculation: a double-blind, randomized, placebo-controlled study with fluoxetine, fluvoxamine, paroxetine and sertra-line. J. Clin. Psychopharmacol. (1998) 18:274–281.
   PubMed Web of Science ®Google Scholar
• PRICE JS, WALLER PC, WOOD SM et al.:A comparison of the post-marketing safety of four selective serotonin re-uptake inhibitors including the investigation of symptoms occurring on withdrawal. Br. J. Clin. Pharmacol. (1996) 42:757–763.
   PubMed Web of Science ®Google Scholar
• MICHELSON D, TAMURA R, TEPNER R et al:Physiological correlates of SSRI withdrawal: Evidence from a controlled, randomized trial of fluoxetine, sertraline and paroxetine. American College of Neuropsychophar-macology Meeting. Puerto Rico, USA (1998).
   Google Scholar
• MARKOWITZ JS, DEVANE CL, LISTON HL et al:An assess-ment of selective serotonin re-uptake inhibitor discontinuation symptoms with citalopram. Int. Clin. Psychopharmacol. (2000) 15:329–333.
   PubMed Web of Science ®Google Scholar
• RASMUSSEN SL, OVERO KF, TANGHOJ P: Cardiac safety of citalopram: prospective trials and retrospective analyses. J. Clin. Psychopharmacol. (1999) 19:407–415.
   PubMed Web of Science ®Google Scholar
• COUPLAND N, WILSON S, NUTT D: Antidepressant drugs and the cardiovascular system: a comparison of tricylics and selective serotonin re-uptake inhibitors and their relevance for the treatment of psychiatric patients with cardiovascular problems. J Psychophar-macol. (1997) 11:83–92.
   PubMed Web of Science ®Google Scholar
• FAIRWEATHER DB, POZZO CD, KERR JS et al.: Citalo-pram compared to dothiepin and placebo: Effects on cognitive function and psychomotor performance. Human Psychopharmacology Clinical & Experimental (1997) 12:119–126.
   Google Scholar
• LADER M, MELHUISH A, FRCKA G et al.: The effects ofcitalopram in single and repeated doses and with alcohol on physiological and psychological measures in healthy subjects. Eur. J. Clin. Pharmacol. (1986) 31:183–190.
   PubMedGoogle Scholar
• FAVA M: Weight gain and antidepressants. J. Clin. Psychiatry (2000) 61:37–41.
   PubMed Web of Science ®Google Scholar
• WADE A, OVERO KF, LEMMING O: Weight monitoring during two long-term studies of citalopram. European College of Neuropsychopharmacology Meeting. London, UK (1999).
   Google Scholar
• BARBEY JT, ROOSE SP: SSRI safety in overdose. J. Clin. Psychiatry (1998) 5 9 (Suppl. 15):42–48.
   Google Scholar
• OSTROM M, ERIKSSON A, THORSON J et al.: Fatal overdose with citalopram [letter] [see comments]. Lancet (1996) 3 4 8:339–340.
   Google Scholar
• PERSONNE M, SJOBERG G, PERSSON H: Citalopram overdose-review of cases treated in Swedish hospitals [published erratum appears in J. Toxicol. Clin. Toxicol. 1997;35(5):577]. j Toxicol Clin. Toxicol. (1997) 35:237–240.
   Google Scholar
• FU K, KONRAD RJ, HARDY RW et al: An unusual multiple drug intoxication case involving citalopram. J Anal. Toxicol (2000) 24:648-650. [In Process].
   Google Scholar
• FREY R, SCHREINZER D, STIMPFL T et al.: Suicide by antidepressant intoxication identified at autopsy in Vienna. Eur. Neuropsychopharmacol. (2000) 10:133–142.
   PubMed Web of Science ®Google Scholar
• MUSSHOFF F, SCHMIDT P, MADEA B: Fatality caused by a combined trimipramine-citalopram intoxication. Forensic Sci. Int. (1999) 106:125–131
   PubMedGoogle Scholar
• AVENOSO A, FACCIOLA G, SCORDO MG et al.: No effect of citalopram on plasma levels of clozapine, risperi-done and their active metabolites in patients with chronic schizophrenia. Clinical Drug Investigation (1998) 16:393–398.
   Web of Science ®Google Scholar
• SYVALAHTI EKG, TAIMINEN T, SAARIJARVI S et al: Citalo-pram causes no significant alterations in plasma neuroleptic levels in schizophrenic patients. J Int. Med. Res. (1997) 25:24–32.
   PubMedGoogle Scholar
• GRAM LF, HANSEN MG, SINDRUP SH et al.: Citalopram: interaction studies with levomepromazine, imipramine and lithium. Ther. Drug Monit. (1993) 15:18–24.
   PubMed Web of Science ®Google Scholar
• MOLLER SE, LARSEN F, KHAN AZ et al.: lack of effect of citalopram on the steady-state pharmacokinetics of carbamazepine in healthy male subjects. J Clin. Psycho-pharmacol (2001). (In Press).
   Google Scholar
• NOLTING A, ABRAMOWITZ W: Lack of interaction between citalopram and the CYP3A4 substrate triazolam. Pharmacotherapy (2000) 20:750–755.
   PubMedGoogle Scholar
• MOLLER SE, LARSEN F, PITSIU M et al.: Effect of citalo-pram on oral theophylline pharmacokinetics. Clin. Ther. (2000) 2 2 :1494–1501.
   Google Scholar
• GUTIERREZ M, ABRAMOWITZ W: Lack of effect of a single dose of ketoconazole on the pharmacokinetics of citalopram. Pharmacotherapy (2001) 21:163–168.
   PubMedGoogle Scholar
• Prescribing information for Celexa (citalopram Hbr). U.S. Food and Drug Administration, Rockville, MD, USA (1998).
   Google Scholar
• PRISKORN M, SIDHU JS, LARSEN F eta/.:Investigation of multiple dose citalopram on the pharmacokinetics and pharmacodynamics of racemic warfarin. Br. J Clin. Pharmacol. (1997) 44:199–202.
   Google Scholar
• LARSEN F, PRISKORN M, SEGONZAC A et al: Coadminis-tration of citalopram and digoxin in healthy volunteers. American College of Neuropsychopharma-cology Meeting. Kamuela, HI, USA (1997).
   Google Scholar
• HAKKARAINEN H, HOPFNER PETERSEN H: Treatment emergent adverse events in elderly depressed patients: Double-blind comparison between citalo-pram and other SSRIs. American Psychiatric Association Meeting. Toronto, Ontario, Canada (1998).
   Google Scholar
• WISNER KL, PEREL JM, FINDLING RL: Antidepressant treatment during breast-feeding [see comments]. Am. J. Psychiatry (1996) 153:1132–1137.
   PubMed Web of Science ®Google Scholar
• ERICSON A, KALLEN B, WIHOLM BE: Delivery outcome after the use of antidepressants in early pregnancy. Eur.j Clin. Pharmacol. (1999) 55:503–508.
   PubMed Web of Science ®Google Scholar
• LEPOLA U, PENTTINEN J, KOPONEN H et al.: Citalopram treatment and breastfeeding. Annual Meeting of the New Clinical Drug Evaluation Unit. Boca Raton, FL, USA (2000).
   Google Scholar
• SPIGSET O, CARLEBORG L, OHMAN R et al.:Ex cr etion of citalopram in breast milk. Br. J Clin. Pharmacol (1997) 44:295–298.
   PubMed Web of Science ®Google Scholar
• RAMPONO J, KRISTENSEN JH, HACKETT LP et al.: Citalo-pram and demethylcitalopram in human milk; distribution, excretion and effects in breast fed infants. Br. J. Gun. Pharmacol. (2000) 50:263–268.
   Google Scholar
• SCHMIDT K, OLESEN OV, JENSEN PN: Citalopram and breast-feeding: serum concentration and side effects in the infant. Biol. Psychiatry (2000) 47:164–165.
   PubMed Web of Science ®Google Scholar
• JENSEN PN, OLESEN OV, BERTELSEN A et al.: Citalopram and desmethylcitalopram concentrations in breast milk and in serum of mother and infant. Thor. Drug Monit. (1997) 19:236–239.
   PubMed Web of Science ®Google Scholar